Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$830.59 USD

830.59
349,421

+13.94 (1.71%)

Updated Nov 7, 2024 12:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Company News for Sep 9, 2022

Companies in The News Are: REGN, JPM, CASY, GME

Regeneron (REGN) Up on Higher Dose Eye Drug Studies Success

Regeneron (REGN) stock jumps as aflibercept 8 mg with 12- and 16-week dosing regimens in patients with DME and wAMD meet primary goals.

SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma

Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.

Regeneron (REGN) Down 2.3% Since Last Earnings Report: Can It Rebound?

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should Invesco S&P 500 GARP ETF (SPGP) Be on Your Investing Radar?

Style Box ETF report for SPGP

Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why

Kodiak Sciences (KOD) has progressed well with the development of its lead pipeline candidate, tarcocimab, for treating various retinal vascular diseases.

Kodiak Sciences (KOD) Focuses on Developing Eye Drug Tarcocimab

Kodiak Sciences (KOD) lead pipeline candidate, tarcocimab, being developed for treating various retinal vascular diseases, holds potential. Stiff competition in the market remains a woe.

Sanofi (SNY) Ends Development of Breast Cancer Drug, Stock Down

Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.

Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus

Kodiak Sciences (KOD) reports narrower-than-expected loss for the second quarter of 2022. The focus is on the lead candidate, KSI-301, which is being developed for treating various retinal vascular diseases.

Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat

Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q2

Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2022.

Company News for Aug 4, 2022

Companies in The News Are: MRNA, REGN, HZNP, EXC

Regeneron (REGN) Q2 Earnings & Sales Beat on Eylea, Dupixent

Regeneron (REGN) tops earnings and sales in the second quarter, driven by its lead drug Eylea and profits from asthma drug Dupixent. However, earnings decline year over year.

U.S. Stock Futures Rise on Strong Q2 Earnings

Stock futures have risen in today¿¿¿s pre-market after two consecutive days of loss making.

Pre-markets Green on Strong Earnings Numbers

Pre-markets Green on Strong Earnings Numbers.

Regeneron (REGN) Q2 Earnings and Revenues Beat Estimates

Regeneron (REGN) delivered earnings and revenue surprises of 14.54% and 3.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q2

Alnylam's (ALNY) earnings and sales fall shy of estimates in the second quarter of 2022. The company maintains its revenue guidance for 2022.

What is in Store for Regeneron (REGN) This Earnings Season?

Regeneron's (REGN) second-quarter earnings might have gotten a boost from the solid performance of Eylea and Dupixent.

Sanofi (SNY) Q2 Earnings & Sales Beat, Ups 2022 Growth View

Sanofi (SNY) beats second-quarter estimates for earnings and sales. Dupixent drives sales growth and a strong recovery in travel vaccines. The company raises its earnings growth guidance for 2022.

Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know

Regeneron (REGN) closed the most recent trading day at $587.28, moving +0.2% from the previous trading session.

Roche (RHHBY) 1H22 Earnings, Sales Grow, View Disappoints

Roche (RHHBY) performance in the first half was decent on demand for its diagnostics base business and new drugs. Demand for COVID-19 tests is likely to fall in the second half.

Regeneron (REGN) Gains But Lags Market: What You Should Know

Regeneron (REGN) closed at $595.73 in the latest trading session, marking a +1.54% move from the prior day.

Roche (RHHBY) Announces 2-Year Data on Vabysmo for nAMD

Roche's (RHHBY) new two-year data reinforce the long-term efficacy, safety and durability of Vabysmo in wet age-related mtacular degeneration.